APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021

Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021

WALTHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 at 4:30 p.m. ET.

The event will be available live by dialing (866) 774-0323 (Domestic) or (602) 563-8683 (International) and entering the conference ID # 6956712 or via webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at . A replay of the webcast will be available for 90 days following the event.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit .

Investor Contact:

Argot Partners



+1 212.600.1902



EN
18/02/2021

Underlying

APLSApellis Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

Wedbush Research
  • Wedbush Research
PHM PULTEGROUP INC.
NVCR NOVOCURE LTD.
MNKD MANNKIND CORP.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ACRS ACLARIS THERAPEUTICS INC.
DHI D.R. HORTON INC.
BLDR BUILDERS FIRSTSOURCE INC.
ARGX ARGENX ADS
APLS APELLIS PHARMACEUTICALS
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
UFPI UFP INDUSTRIES INC.
JANX JANUX THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
6h / 11m 6h / 11m 1 EN
David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Dylan Shindler
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
MNKD MANNKIND CORP.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ACRS ACLARIS THERAPEUTICS INC.
APLS APELLIS PHARMACEUTICALS
REPL REPLIMUNE GROUP
JANX JANUX THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
7h / 14m 7h / 14m 1 EN
Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
U INC.
VRDN UNITY SOFTWARE
PHVS VIRIDIAN THERAPEUTICS INC
STX PHARVARIS NV
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD APPLOVIN CORP
ATXS THE TRADE DESK
GFS INC.
EWTX ASTRIA THERAPEUTICS INC
GLOBALFOUNDRIES INC
EDGEWISE THERAPEUTICS INC
07/17/25 July 17, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
BIIB BIOGEN INC.
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
STOK STOKE THERAPEUTICS
VRDN VIRIDIAN THERAPEUTICS INC
PHVS PHARVARIS NV
ATXS ASTRIA THERAPEUTICS INC
EWTX EDGEWISE THERAPEUTICS INC
07/17/25 July 17, 2025 1 EN
Free Trial
APLS Apellis Pharmac...

Apellis Pharmaceuticals Inc: 1 director

A director at Apellis Pharmaceuticals Inc sold after exercising options/sold 139,365 shares at 20.185USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...

APLS APELLIS PHARMACEUTICALS
07/16/25 July 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch